Ozawa Yuri, Kobori Hiroyuki
Dept. of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112-2699, USA.
Am J Physiol Renal Physiol. 2007 Jul;293(1):F100-9. doi: 10.1152/ajprenal.00520.2006. Epub 2007 Apr 4.
This study was performed to determine the effectiveness of the Rho kinase inhibitor and NF-kappaB inhibitor in renal injury of ANG II-infused hypertensive rats. Male Sprague-Dawley rats, maintained on a normal diet, received either a sham operation (n = 7) or continuous ANG II infusion (120 ng/min) subcutaneously via minipumps. The ANG II-infused rats were further subdivided into three subgroups (n = 7 each) to receive one of the following treatments during the entire period: vehicle, Rho kinase inhibitor (fasudil; 3 mg.kg(-1).day(-1) ip), or NF-kappaB inhibitor (parthenolide; 1 mg.kg(-1).day(-1) ip). After 12 days of ANG II infusion, systolic blood pressure (BP; 208 +/- 7 vs. 136 +/- 3 mmHg), Rho kinase activity, NF-kappaB activity, renal ANG II contents (160 +/- 25 vs. 84 +/- 14 pg/g), monocytic chemotactic protein (MCP) 1 mRNA, interstitial macrophage infiltration, transforming growth factor-beta1 (TGF-beta1) mRNA, interstitial collagen-positive area, urinary protein excretion (43 +/- 6 vs. 11 +/- 2 mg/day), and urinary albumin excretion were significantly enhanced compared with the Sham group. While fasudil or parthenolide did not alter systolic BP (222 +/- and 190 +/- 21, respectively), both treatments completely blocked ANG II-induced enhancement of NF-kappaB activity, renal ANG II contents (103 +/- 11 and 116 +/- 21 pg/g, respectively), MCP1 mRNA, interstitial macrophage infiltration, TGF-beta1 mRNA, interstitial collagen-positive area, urinary protein excretion (28 +/- 6 and 23 +/- 3 mg/day, respectively), and urinary albumin excretion. Importantly, parthenolide did not alter ANG II-induced Rho kinase activation although fasudil abolished ANG II-induced Rho kinase activation. These data indicate that the Rho-NF-kappaB axis plays crucial roles in the development of ANG II-induced renal injury independently from BP regulation.
本研究旨在确定Rho激酶抑制剂和核因子-κB(NF-κB)抑制剂对血管紧张素II(ANG II)输注所致高血压大鼠肾损伤的疗效。雄性Sprague-Dawley大鼠维持正常饮食,接受假手术(n = 7)或通过微型泵皮下持续输注ANG II(120 ng/min)。将输注ANG II的大鼠进一步分为三个亚组(每组n = 7),在整个实验期间接受以下一种治疗:溶剂对照、Rho激酶抑制剂(法舒地尔;3 mg·kg⁻¹·d⁻¹,腹腔注射)或NF-κB抑制剂(小白菊内酯;1 mg·kg⁻¹·d⁻¹,腹腔注射)。输注ANG II 12天后,与假手术组相比,收缩压(BP;208±7 vs. 136±3 mmHg)、Rho激酶活性、NF-κB活性、肾ANG II含量(160±25 vs. 84±14 pg/g)、单核细胞趋化蛋白(MCP)1 mRNA、间质巨噬细胞浸润、转化生长因子-β1(TGF-β1)mRNA、间质胶原阳性面积、尿蛋白排泄(43±6 vs. 11±2 mg/天)和尿白蛋白排泄均显著增加。虽然法舒地尔或小白菊内酯均未改变收缩压(分别为222±和190±21),但两种治疗均完全阻断了ANG II诱导的NF-κB活性增强、肾ANG II含量(分别为103±11和116±21 pg/g)、MCP1 mRNA、间质巨噬细胞浸润、TGF-β1 mRNA、间质胶原阳性面积、尿蛋白排泄(分别为28±6和23±3 mg/天)以及尿白蛋白排泄。重要的是,尽管法舒地尔消除了ANG II诱导的Rho激酶激活,但小白菊内酯并未改变ANG II诱导的Rho激酶激活。这些数据表明,Rho-NF-κB轴在ANG II诱导的肾损伤发展中起关键作用,独立于血压调节。